{"id":"NCT00383552","sponsor":"Organon and Co","briefTitle":"Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)","officialTitle":"A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-08","completion":"2008-08","firstPosted":"2006-10-03","resultsPosted":"2011-10-25","lastUpdate":"2024-05-17"},"enrollment":746,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID","otherNames":["SCH 418131"]},{"type":"DRUG","name":"Mometasone Furoate MDI (MF MDI)","otherNames":["SCH 32088"]},{"type":"DRUG","name":"Formoterol Fumarate 10 mcg","otherNames":["Foradil"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MF/F MDI 100/10 mcg BID","type":"EXPERIMENTAL"},{"label":"MF MDI 100 mcg BID","type":"EXPERIMENTAL"},{"label":"F MDI 10 mcg BID","type":"EXPERIMENTAL"},{"label":"Placebo BID","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week double-blind Treatment Period, participants will receive open-label (OL) MF MDI 100 mcg twice daily (BID) for 2 to 3 weeks during the Run-in Period. Efficacy will be measured by the Area Under the Curve from 0 to 12 hours \\[AUC\\](0-12 hours) of the change from Baseline to the Week 12 Endpoint in Forced Expiratory Volume in One Second (FEV1) and by the time-to-first severe asthma exacerbation across the 26-week treatment period.","primaryOutcome":{"measure":"Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"MF/F MDI 100/10 mcg BID","deltaMin":3.94,"sd":3.29},{"arm":"MF MDI 100 mcg BID","deltaMin":1.85,"sd":3.29},{"arm":"F MDI 10 mcg BID","deltaMin":4.09,"sd":3.29},{"arm":"Placebo BID","deltaMin":1.64,"sd":3.29}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":22},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21828036"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":882},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","HEADACHE","NASOPHARYNGITIS"]}}